Inventor · disambiguated record
Jennifer Marie Mataraza
Also filed as: MATARAZA JENNIFER MARIE
19 granted patents·14 pending applications·408 citations·filing 2010–2025
96Inventor score
Top patents by PatentIndex Score
33 records- 0199US9683048B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2015·Granted Jun 20, 2017·115 cites·144 claims
- 0298US10981990B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2020·Granted Apr 20, 2021·11 cites·30 claims
- 0398US10711060B2Antibody molecules to LAG-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Jul 14, 2020·29 cites·5 claims
- 0498US9815898B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2017·Granted Nov 14, 2017·35 cites·30 claims
- 0598US9605070B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2015·Granted Mar 28, 2017·67 cites·85 claims
- 0697US10851165B2Antibody molecules to PD-L1 and methods of treating cancerNOVARTIS AG·Filed 2018·Granted Dec 1, 2020·10 cites·80 claims
- 0797US9988452B2Antibody molecules to PD-L1 and uses thereofNOVARTIS AG·Filed 2015·Granted Jun 5, 2018·30 cites·27 claims
- 0896US10752687B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2017·Granted Aug 25, 2020·6 cites·90 claims
- 0996US9908936B2Antibody molecules to LAG-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Mar 6, 2018·23 cites·30 claims
- 1095US11155620B2Method of detecting TIM-3 using antibody molecules to TIM-3NOVARTIS AG·Filed 2019·Granted Oct 26, 2021·6 cites·20 claims
- 1194US11827704B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2020·Granted Nov 28, 2023·2 cites·43 claims
- 1293US10472419B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Nov 12, 2019·12 cites·57 claims
- 1393US9884913B2Antibody molecules to TIM-3 and uses thereofNOVARTIS AG·Filed 2017·Granted Feb 6, 2018·12 cites·30 claims
- 1493US8563694B2Fully human antibodies to BTLAMATARAZA JENNIFER MARIE·Filed 2010·Granted Oct 22, 2013·39 cites·8 claims
- 1590US2025066479A1Antibody molecules to pd-1 and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1688US9346882B2Fully human antibodies to BTLAMEDAREX LLC·Filed 2013·Granted May 24, 2016·9 cites·22 claims
- 1786US11413340B2Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2016·Granted Aug 16, 2022·2 cites·32 claims
- 1886US2024343808A1Antibody molecules to pg-l1 and methods of treating cancer and infectious diseasesNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1978US2022185883A1Method of detecting tim-3 using antibody molecules to tim-3NOVARTIS AG·Filed 2021·Application pending·0 cites
- 2076US12186278B2Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2022·Granted Jan 7, 2025·0 cites·27 claims
- 2175US2025382365A1Antibody molecules to lag-3 and uses thereofNOVARTIS AG·Filed 2025·Application pending·0 cites
- 2273US12252535B2Antibody molecules to LAG-3 and uses thereofNOVARTIS AG·Filed 2020·Granted Mar 18, 2025·0 cites·10 claims
- 2373US2021284737A1Antibody molecules to pd-l1 and uses thereofNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2470US2022133889A1Combination therapies comprising antibody molecules to tim-3NOVARTIS AG·Filed 2021·Application pending·0 cites
- 2567US2023013364A1Combination therapies comprising antibody molecules to pd-1NOVARTIS AG·Filed 2021·Application pending·0 cites
- 2666US2025319179A1Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2025·Application pending·0 cites
- 2759US2019119381A1Fully human antibodies to btlaSQUIBB & SONS LLC·Filed 2018·Application pending·0 cites
- 2856US10155813B2Fully human antibodies to BTLASQUIBB & SONS LLC·Filed 2016·Granted Dec 18, 2018·0 cites·4 claims
- 2956US2018207273A1Combination therapies comprising antibody molecules to tim-3DRANOFF GLENN·Filed 2016·Application pending·0 cites
- 3053US2015259420A1Antibody molecules to lag-3 and uses thereofNOVARTIS AG·Filed 2015·Application pending·0 cites
- 3147US2018222982A1Combination therapies comprising antibody molecules to pd-1DRANOFF GLENN·Filed 2016·Application pending·0 cites
- 3242US2020277378A1Combination therapiesNOVARTIS AG·Filed 2018·Application pending·0 cites
- 3340US2018340025A1Combination therapies comprising antibody molecules to lag-3NOVARTIS AG·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →